Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments

RS Duman, G Sanacora, JH Krystal - Neuron, 2019‏ - cell.com
The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …

Mechanisms of ketamine action as an antidepressant

P Zanos, TD Gould - Molecular psychiatry, 2018‏ - nature.com
Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

K Hashimoto - Psychiatry and clinical neurosciences, 2019‏ - Wiley Online Library
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

[HTML][HTML] Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions

MV Fogaça, RS Duman - Frontiers in cellular neuroscience, 2019‏ - frontiersin.org
Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical
and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be …

The future of rodent models in depression research

A Gururajan, A Reif, JF Cryan, DA Slattery - Nature Reviews …, 2019‏ - nature.com
Currently, over 300 million people worldwide have depression, and the socioeconomic
burden of this debilitating disorder is anticipated to increase markedly over the coming …

NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine

P Zanos, KA Brown, P Georgiou, P Yuan… - Journal of …, 2023‏ - jneurosci.org
Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the
relevance of this pharmacology to its rapid (within hours of administration) antidepressant …

GABAA receptors as targets for treating affective and cognitive symptoms of depression

B Luscher, JL Maguire, U Rudolph, E Sibille - Trends in pharmacological …, 2023‏ - cell.com
In the past 20 years, our understanding of the pathophysiology of depression has evolved
from a focus on an imbalance of monoaminergic neurotransmitters to a multifactorial picture …

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders

T Prévot, E Sibille - Molecular psychiatry, 2021‏ - nature.com
Cognitive dysfunctions, including impaired attention, learning, memory, planning and
problem solving, occur in depressive episodes, often persist during remission, predict …

Dual action of ketamine confines addiction liability

LD Simmler, Y Li, LC Hadjas, A Hiver, R Van Zessen… - Nature, 2022‏ - nature.com
Ketamine is used clinically as an anaesthetic and a fast-acting antidepressant, and
recreationally for its dissociative properties, raising concerns of addiction as a possible side …

Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms

A Inserra, D De Gregorio, G Gobbi - Pharmacological Reviews, 2021‏ - Elsevier
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …